Gongora et al. reported a significant reduction in all-cause mortality and cardiovascular events, including heart failure incidence, heart failure-related hospitalizations, new-onset cardiomyopathy, and clinically significant arrhythmias, in diabetic patients treated with SGLT2 inhibitors during anthracycline-based chemotherapy for hematologic malignancies [64]. Here, SLC5A2 is linked to cardiomyopathy.